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and human cartilage in knee osteoarthritis with




Introduction: This is a series of clinical case reports demonstrating that a combination of percutaneously injected
autologous adipose-tissue-derived stem cells, hyaluronic acid, platelet rich plasma and calcium chloride may be
able to regenerate bones in human osteonecrosis, and with addition of a very low dose of dexamethasone,
cartilage in human knee osteoarthritis.
Case reports: Stem cells were obtained from adipose tissue of abdominal origin by digesting lipoaspirate tissue
with collagenase. These stem cells, along with hyaluronic acid, platelet rich plasma and calcium chloride, were
injected into the right hip of a 29-year-old Korean woman and a 47-year-old Korean man. They both had a history
of right hip osteonecrosis of the femoral head. For cartilage regeneration, a 70-year-old Korean woman and a
79-year-old Korean woman, both with a long history of knee pain due to osteoarthritis, were injected with stem
cells along with hyaluronic acid, platelet rich plasma, calcium chloride and a nanogram dose of dexamethasone.
Pre-treatment and post-treatment MRI scans, physical therapy, and pain score data were then analyzed.
Conclusions: The MRI data for all the patients in this series showed significant positive changes. Probable bone
formation was clear in the patients with osteonecrosis, and cartilage regeneration in the patients with
osteoarthritis. Along with MRI evidence, the measured physical therapy outcomes, subjective pain, and functional
status all improved. Autologous mesenchymal stem cell injection, in conjunction with hyaluronic acid, platelet rich
plasma and calcium chloride, is a promising minimally invasive therapy for osteonecrosis of femoral head and, with
low-dose dexamethasone, for osteoarthritis of human knees.
Background
Adipose-tissue-derived stem cells (ADSCs) have been
widely used in Korea over the last few years by plastic
surgeons as a semi-permanent volume expander. In June
2009, the Korean Food and Drug Administration
(KFDA) allowed ADSCs to be used as autologous cell
transplant when obtained and processed within a medi-
cal clinic with minimal processing [1].
Mesenchymal stem cells (MSCs) are found in numer-
ous human tissues including bone marrow, synovial
tissue and adipose tissue. These have been shown to
differentiate into bones, cartilage, muscle and adipose
tissue, representing a promising new area of therapy in
regenerative medicine [2].
Because of their potent capabilities, MSCs have been
used successfully in animal models to regenerate carti-
lage and bones [3,4]. In 2008, Centeno and colleagues
reported regeneration of knee cartilage in a human by
using autologous culture-expanded bone-marrow-
derived stem cells [5]. However, to the best of our
knowledge ADSCs have never been used successfully in
osteonecrosis of a femoral head and in osteoarthritis of
a human knee.
Osteonecrosis, or avascular necrosis, of femoral head
is relatively a common disorder affecting individuals in
their 30s to 50s. Osteoarthritis of a knee is an even
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more common disorder, especially in older patients.
Currently, the only cure for both diseases is surgical
intervention. However, the successful regeneration of
bones and cartilage with ADSCs may represent a pro-
mising new, minimally invasive, non-surgical alternative.
Many issues need to be resolved and clarified before
the general application of the procedure. The mechan-
ism of regeneration is not yet clear. It could be through
direct differentiation of stem cells that were introduced
to the diseased joints. Alternatively, it could be due to
the tropic effects of ADSCs on the existing tissues.
Further, various elements of the local environment can
affect the differentiation of MSCs [6]. Also, it is believed
that a scaffolding material might be needed to allow the
MSCs to attach and engraft [7].
Platelet-rich plasma (PRP) was used as a growth factor
and as a differentiating agent for the MSCs. PRP con-
tains multiple growth factors including transforming
growth factor (TGF)b, insulin-like growth factor (IGF),
fibroblast growth factor (FGF), and platelet-derived
growth factor (PDGF). A literature review of the data on
PRP shows that it has a positive effect on the stimula-
tion of bones, blood vessel and chondrocyte formation
[8-10]. Hyaluronic acid was added as a scaffolding mate-
rial, and calcium chloride was used as a PRP-activating
agent [11].
This series of case reports demonstrates successful
clinical results of regenerating bones in osteonecrosis
and cartilage in patients with osteoarthritis, using percu-
taneously implanted, autologous MSCs along with PRP,
hyaluronic acid, calcium chloride (CaCl2) and very-low-
dose dexamethasone.
Case presentations
The following cases concern four different individuals.
Of the four, the first two cases involve bone regenera-
tion in osteonecrosis of hips, the latter two cases regen-
eration of cartilage in osteoarthritis of knees.
The first case concerns a 29-year-old Korean woman
with over a year’s history of right hip pain due to
osteonecrosis.
Approximately a year prior to presentation, she started
having hip pain with no history of trauma. She was seen
by a physician and was diagnosed with osteoarthritis of
the hip after an MRI scan. After taking non-steroidal
anti-inflammatory drugs (NSAIDs) for a few weeks, her
hip pain improved. About a month prior to presenta-
tion, she again started having hip pain radiating to the
anterior region of the right knee. The pain was worse
when standing up, walking, and exercising. The pain
improved with rest. However, this time, the pain was
not greatly relieved with NSAIDs.
A repeat MRI showed osteonecrosis of the femoral
head, stage 4. Since there is no effective non-surgical
treatment of the disease, she elected to receive stem cell
treatment.
At the time of initial evaluation, she reported moder-
ately severe pain (visual analog scale (VAS) score 7) on
rest, increased pain when standing and walking (VAS
score 9).
For a week prior to liposuction, she was restricted
from taking corticosteroids, aspirin, NSAIDs, and orien-
tal herb medications.
For the liposuction procedure, she was brought into
an operating room and placed in a supine position. She
was then sedated with propofol 2 mg intravenously
(push) and a 20 mg/hour rate of continuous infusion.
After cleaning her abdominal area with povodine-
iodine and placing sterile drapes, an incision of approxi-
mately 0.5 cm was made approximately 5 cm below the
umbilicus. Then, using tumescent solution (500 cm3
normal saline, 40 cm3 2% lidocaine, 20 cm3 0.5% mar-
caine, 0.5 cm3 epinephrine 1:1000), the lower abdomen
area was anesthetized. Next, using a 3.0 Hartman can-
nula, a total of 160 cm3 of lipoaspirates were extracted
and separated by gravity. The resulting 100 cm3 of adi-
pose tissue was then centrifuged at 3500 rpm for five
minutes. The end result was approximately 40 cm3 of
packed adipose tissue, fibrous tissue, red blood cells and
a small number of nucleated cells.
An equal volume of digestive enzyme, 0.07% collage-
nase type 1, composed of several collagenases, sulfhydryl
protease, clostripain, a trypsin-like enzyme, and a amino
peptidase, derived from Clostridium histolyticum (Adi-
lase; Worthington, Lakewood, NJ, USA) was then mixed
with the centrifuged lipoaspirates at a ratio of 1:1 and
digested for 30 minutes at 37°C while rotating [12].
Bacterial collagenases differ from vertebrate collage-
nases in that they exhibit broader substrate specificity
[13].
After the digestion, the lipoaspirates were centrifuged at
100g for three minutes to separate the lipoaspirate and
the enzyme. The leftover enzyme was then removed.
Using 500 cm3 5% dextrose in lactated Ringer’s solu-
tion, the lipoaspirates were washed three times to
remove the collagenase. After each washing, the lipoas-
pirates were centrifuged at 100 g. After the last centri-
fuge process, approximately 10 cm3 of ADSCs were
obtained.
While preparing the ADSCs, 30 cm3 of autologous
blood was drawn with 2.5 cm3 of anticoagulant citrate
dextrose solution (ACD) formula. This was centrifuged
at 200 g for five minutes. The resultant supernatant was
drawn and centrifuged at 1000 g for five minutes. The
supernatant was drawn and discarded. The resulting
buffy coat was mixed with 10 cm3 of ADSCs.
Hyaluronic acid 1 cm3 was added to this mixture to
act as a scaffold. This PRP was again mixed with CaCl2
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for activation of platelets at a ratio of 10:2 (PRP 10:2
CaCl2).
In order to inject the mixture of stem cells and PRP,
our patient was first placed in a lateral position with her
left side down. After cleaning with povodine-iodine and
draping with sterile drapes, 2% lidocaine was used to
anesthetize the hip at the femoral head region. Using a
22-gauge 3.5-inch needle, 17 cm3 mixture of ADSCs,
PRP, hyaluronic acid and CaCl2 were injected into the
femoral head under ultrasound guidance.
She was then instructed to remain still with her leg
elevated for 30 minutes to allow for cell attachment. On
discharge home, she was instructed to maintain activity
as tolerated. She returned to the clinic for four addi-
tional PRP injections with calcium chloride every week
over a period of a month.
After the fourth week of the ADSC injection, her pain
had improved more than 50%. By week 12, her pain had
improved more than 70% along with an improvement in
range of motion (Tables 1 and 2). A repeat MRI taken
at week 12 showed a significant filling of bone defects
on the superior acetabulum and probable bone matrix
formation in the subcortical region of the femoral head
(Figure 1).
The second case concerns a 47-year-old Korean man
who had been working as a diver until three years prior
to presentation.
Approximately three years prior to presentation, he
started having right hip pain and was diagnosed with
osteonecrosis of the right hip. His pain had progressed
over three years and he was offered a total hip replace-
ment (THR). Being reluctant to proceed with the surgi-
cal procedure, he elected to proceed with stem cell
treatment. Before the procedure, a repeat MRI of the
hip was performed and a diagnosis of osteonecrosis of
the femoral head, stage 4, was confirmed.
He then underwent the same procedures as our first
patient. After the fourth week of the ADSC injection,
his pain improved more than 30% along with improve-
ment in range of motion. However, by week 12, his pain
had only minimally improved further (Tables 3 and 4).
Interestingly, a repeat MRI taken at week 12 showed a
significant filling of bone defects with a possibility of
bone matrix formation at the site of necrosis in the
femoral head (Figure 2).
The third case concerns a 70-year-old Korean woman
with over five years’ history of right knee pain due to
osteoarthritis.
Due to her occupation, she made active use of her bilat-
eral knee joints. With a diagnosis of osteoarthritis of the
right knee, she had received multiple injections of steroids
and hyaluronic acid over the years. However, she did not
notice any improvement in her pain. She was seen by an
orthopedic surgeon and was offered a total knee replace-
ment (TKR). She was reluctant to go through the TKR
procedure due to possible side effects. Since then, she has
been receiving physical therapy with little improvement.
At the time of initial evaluation, she reported moder-
ately severe pain (VAS score 7) on rest. Her knee pain
increased when walking. She also complained of mild
knee swelling. On physical examination, there was mild
joint swelling, a decreased range of motion and tender-
ness with flexion. Apley and McMurray tests were nega-
tive, and there was no ligament laxity.
A pre-treatment 1.5T MRI scan demonstrated a
decreased size and deformed contour on the medial
meniscus of the left knee due to maceration.
After obtaining ADSCs and preparing PRP as described
above for the first two patients, she was prepared for
injection of the mixture into the joint.
In order to inject the stem cell and PRP mixture, she
was first placed in a supine position with her right knee
bent at 90°. After cleaning with povodine-iodine and
draping with sterile drapes, her knee was anesthetized
with 2% lidocaine at the medial and lateral sides of the
inferior patella. Using a 22-gauge 1-inch needle, 8.5 cm3
of ADSCs, PRP, dexamethasone and hyaluronic acid
mixture was injected into the medial and the lateral
sides of the knee.
She was then instructed to remain still for 30 minutes
to allow for cell attachment. As she was subsequently
discharged from the clinic, she was instructed to main-
tain activity as tolerable.
She returned to our clinic for four additional PRP and
dexamethasone injections over the next four weeks.
After the seventh week of ADSC injection, her pain had
improved more than 80% and flexion of the knee had
also improved. By week 12, her pain had improved
more than 90% and the range of motion also further
improved (Tables 5 and 6). A post-treatment MRI taken
at week 12 showed a significant increase in the thickness
of meniscus cartilage on the medial side of the right
knee (Figures 3 and 4).
The final case concerns a 79-year-old Korean woman
with over seven years’ history of bilateral knee pain due
to osteoarthritis.
Her left knee was much more painful than the right.
Due to her occupation, she made active use of her bilat-
eral knee joints. With a diagnosis of osteoarthritis of
Table 1 Functional rating index [16] and visual analog












VAS 7 4 2
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both knees, she had received multiple injections of ster-
oids and hyaluronic acid in both knees over the years.
However, she noticed no improvement of pain. She was
seen by an orthopedic surgeon and was offered a TKR.
She was also reluctant to go through the TKR due to
possible side effects. Since then, she had been receiving
physical therapy with little improvement.
At the time of initial evaluation, she reported severe
pain in the left knee (VAS score 8) on rest. The pain
was increased when walking. On physical examination,
there was deformity of the knee, mild joint swelling, a
decreased range of motion and tenderness with flexion.
Apley and McMurray tests were negative, and there was
no ligamentous laxity.
A pre-treatment 1.5T MRI demonstrated a decreased
size and deformed contour on her medial meniscus of
the left knee due to maceration. She also underwent the
same procedure as our previous patient.
After the fourth week of ADSC injection, her pain
improved over 50% and flexion of the knee improved as
well. By week 12, her pain had improved over 90% and
she was able to flex her knee further (Tables 7 and 8).













Pre-injection evaluation 91 5 20 6 10 7
four weeks post-treatment follow-
up
110 3 35 3 15 3
12 weeks post-treatment follow-up 125 2 40 2 20 2
VAS = visual analog scale.
Figure 1 MRI of the right hip; T1 sequential coronal views. The cavity surrounded by the three green arrows has decreased in size in post-
treatment MRIs due to probable bone regeneration.
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Table 3 Functional rating index and visual analog scale (VAS) score of patient 2
Outcome measures Pre-injection four weeks post-treatment follow-up 12 weeks post-treatment follow-up
Functional rating index 16 12 12
VAS 8 5 5













Pre-injection evaluation 90 8 15 8 10 8
four weeks post-treatment follow-
up
100 5 20 5 10 5
12 weeks post-treatment follow-up 105 5 20 5 15 5
VAS = visual analog scale.
Figure 2 MRI of the right hip; T1 sequential coronal views. The blue arrow shows the pattern of probable bone regeneration. The green
arrow shows probable bone consolidation.
Table 5 Functional rating index and visual analog scale (VAS) score of patient 3
Outcome measures Pre-injection seven weeks post-treatment follow-up 12 weeks post-treatment follow-up
Functional rating index 36 16 13
VAS 7 2 1
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A repeat MRI taken at week 12 showed a significant
increase in the height of her meniscus cartilage on the
anterior medial side of the left knee (Figures 5 and 6).
Discussion
This series of clinical case reports provides clear MRI evi-
dence of apparent bone regeneration in osteonecrosis of
femoral heads and meniscus cartilage regeneration in
osteoarthritis of human knees. Based on the MRI features,
it is probable that the new tissue formation is bone matrix
in the case of osteonecrosis and meniscus cartilage in
osteoarthritis. However, without biopsy, the true nature of
the newly-formed tissue is unclear. While bone and carti-
lage regeneration using ADSCs has been shown in animal
models, these case reports represent the first successful
regeneration of bones and cartilage in human patients.
In addition to the MRI evidence, the patients’ symp-
toms and signs also improved. It is worthwhile to note
that the patients’ symptoms improved gradually over
three months. Thus, it can be speculated that, in
patients with osteonecrosis, newly-formed bone has con-
comitant neovascularization. Osteonecrosis, or avascular
necrosis, occurs due to compromise in blood circulation.
Without concurrent neovascularization, the consolida-
tion or regeneration of bones cannot be sustained.
Table 6 Physical therapy (PT), range of motion of patient 3
PT session VAS score Flexion (degrees) Flexion VAS Extension (degrees) Extension VAS
Pre-injection evaluation 7 110 7 +3 1/10
seven weeks post-treatment follow-up 2 130 3 +5 0/10
12 weeks post-treatment follow-up 1 130 2 +5 0/10
VAS = visual analog scale.
Figure 3 MRI sagittal T2 view of the knee. Pre-treatment and
post-treatment MRI shows increased height of medial meniscus
cartilage and articular cartilage (arrow).
Table 7 Functional rating index and visual analog scale












VAS 8 4 1
Figure 4 MRI coronal T2 view of the knee. Pre-treatment and
post-treatment MRI shows increased height of medial meniscus
(arrow).
Figure 5 MRI sagittal T2 view of the knee. Pre-treatment and
post-treatment MRI shows increased height of medial meniscus
cartilage. The articular cartilage also has a clearer marking,
representing probable cartilage regeneration.
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Another issue with these clinical results is that
patients with osteoarthritis did not report 100% symp-
tom improvements. This may be due to the fact that
osteoarthritis is a disease of the whole knee, not just the
cartilage.
With regard to the mechanism of tissue regeneration,
there are a few plausible possibilities. The mechanism of
regeneration could be through direct differentiation of
stem cells that were introduced through the injection.
However, there is a possibility that the ADSCs exert tro-
pic effects on the existing tissues as well. Numerous stu-
dies have reported that MSCs, in addition to tissue
repair and regenerative effects, have immunomodulatory
and paracrine effects [14].
Furthermore, PRP could have contributed to the regen-
eration of bones and blood vessels. PRP contains multiple
growth factors including TGFb, IGF, FGF, and PDGF. A
literature review of the data on the uses of PRP showed
that it has a positive effect on the stimulation of bones and
blood vessels and chondrocytes. Here, it was used as a
growth factor and as a differentiating agent for the MSCs.
Further, dexamethasone injection, used as a differen-
tiating agent for cartilage, may also have had positive
effects in patients with osteoarthritis. The levels injected
(100 ng/mL) were negligible compared to the doses
being used in clinical settings. Such low doses in the
nanogram range have been shown to increase extracellu-
lar matrix production by chondrocytes, and are com-
monly used in vitro to differentiate MSC from cartilage
[15].
This is the first series of case reports showing possible
successful bone and cartilage regeneration in humans by
using a combination of ADSCs, hyaluronic acid, PRP
and CaCl2. Currently, no non-surgical therapy is avail-
able for the treatment of osteonecrosis and osteoarthri-
tis. Thus, stem cell therapy may significantly improve
current treatment strategies for the treatment of knee
osteoarthritis and osteonecrosis of the femoral head.
However, further studies need to be initiated to find out
the true detailed nature of the apparently regenerated
bones and cartilage and to determine the true mechan-
ism of tissue regeneration.
Conclusions
After three months of treatment, all the patients
reported on above were able to straighten their hips and
extend their knees further, affecting MRI postures.
Therefore, obtaining the post-treatment MRI data at the
exactly same location as pre-treatment MRI of the hips
and knees was difficult.
Although there were difficulties in repeatedly obtaining
the exact location of the hips and knees, the pre-proce-
dure and post-procedure MRI analyses clearly demon-
strate filled bone defects in osteonecrosis and increased
meniscus cartilage volume in osteoarthritis, indicating
regeneration attributable to the ADSC treatment. Addi-
tionally, the measured physical therapy outcomes, subjec-
tive pain, and functional status, all improved
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Figure 6 MRI coronal T2 view of the knee. The anterior medial
meniscus has increased in height.






















1 130 2 +5 0/10
VAS = visual analog scale.
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